Smart Medical, Ireland's Crospon collaborate on stomach surgery

CEO Gadi Terliuc: We offer our capabilities to companies in fields where we probably won't operate, such as stomach shortening procedures.

Smart Medical Systems Ltd. and Ireland's Crospon Ltd. have signed a collaboration agreement to market a combined product for stomach shortening surgical procedures (placement of a gastric band stoma).

Smart Medical will produce a custom version of its NaviAid external channel endoscope accessory for Crospon to permit deployment and positioning of Crospon’s EndoFLIP imaging catheter.

Smart Medical has developed accessories for endoscopes for minimally invasive surgery. Smart Medical CEO Gadi Terliuc told "Globes" that the company was in talks on more agreements.

Smart Medical was founded in 2005 and has received several million dollars in financing from private investors. Terliuc said, "We offer our capabilities to companies in fields where we probably won't operate, such as the stomach shortening procedures market. Crospon has developed a device to precisely measure how much the stomach has been shortened, which saves the surgeon a lot of time. However, they lacked a system to direct their device to the right location, which is where we come in. We've adapted one of our current products to their needs, and the products will be sold as a single system."

Crospon is a fairly new company that already has sales in Europe and US through a distributor Medical Measurement Systems Ltd.

Terliuc declined to disclose details about the agreement with Crospon, saying only, "The share of intellectual property rights is reasonable," implying that Smart Medical will receive royalties on sales.

Smart Medical also has a range of independent products. One product for improving diagnosis of problems in the small intestine, is already sold in Europe by Pentax. Another product for improving diagnosis of problems in the large intestine (via colonoscopy) obtained US Food and Drug Administration (FDA) and EU CE Mark certification this year. The company has begun US sales.

Published by Globes [online], Israel business news - www.globes-online.com - on March 29, 2011

© Copyright of Globes Publisher Itonut (1983) Ltd. 2011

5 Comments
View comments in rows
Update by email about comments talkback
POST
Comments
Your name
Please insert your name
Content
Hyperlink in a new window Hyperlink Right Left underline italic bold Bulleted List Ordered List Face1 Face2 Face3 Face4 Face5 Face6
Your comment

Thanks
You comment was recieved and soon will be published.
In posting comments, I agree to abide by the Terms of Use
Globes encourages lively and frank debate, but posts that the editors consider merely abusive or otherwise inappropriate will be removed. Report inappropriate content
Thank you for posting your comment, which will be reviewed for publication.
Loading Comments...load
Load more comments
MORE FROM GLOBES
Biolight jumps on strong Zacks recommendation

Zacks cites the company for its technology, products, and meeting its targets.

VBL Therapeutics raises $40m in revived Nasdaq IPO

After the fiasco of the failed IPO in August, the drug development company scaled down the offering.

Assuta Hospital Gov't plans taxing private hospitals

The tax is one of the recommendations of the Economic Arrangments bill.

Erez Vigodman Teva boosted by European drug recommendations

Teva's share jumped 4% in Tel Aviv, after climbing 4.9% on Wall Street.

Partner/Orange Partner launches smartphone medical services

The new services includes prescriptions, hospital referrals, and confirmation of illness.

Reuven Krupik Clal Biotech unit PolyHeal nears licensing deal

PolyHeal has signed an MOU with a European drug company for an exclusive global license.

Nasdaq Galmed jumps on FDA hepatitis drug approval

The FDA awarded Fast Track Designation to aramchol for the treatment of Non-Alcoholic Steato-Hepatitis.

artificial sweeteners Weizmann Inst: Sweeteners cause diabetes, obesity

A study found that artificial sweeteners adversely affect intestinal bacteria.

BioCancell share jumps on positive cancer trial results

The clinical trials demonstrated safety and effectiveness of the treatment on high-risk bladder cancer patients.

Trendlines Group set for Toronto IPO

The technological incubators company is raising C$9 at a company value of C$80 million, after money.

Reuven Krupik Clal Biotech sues Hyperion for $200m

Clal Biotechnology alleges Hyperion made "rash and ill-considered" decisions in the Andromeda affair.

pharmaceuticals Clal Biotech: No evidence of misconduct by us

Clal Biotech says documents it was shown by Hyperion do not indicate it committed any misconduct regarding Andromeda.

Soroka Hospital  picture: Eyal Yitzhar Visiting Israel’s wounded at Soroka

Soroka Medical Center in Beersheva, the Israeli hospital closest to Gaza, bears the medical brunt of Operation Protective Edge.

Twitter Facebook Linkedin RSS Newsletters גלובס